UNSPSC 51171947: Lamtidine

This classification denotes a histamine-2 receptor antagonist with the molecular formula C18H28N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BO55Z3JL5K, chemically known as 1-(m-(3-((3-amino-1-methyl-1h-1,2,4-triazol-5-yl)amino)propoxy)benzyl)piperidine but generally known as lamtidine, which bears US NIH Compound Identifier 71988. European Medicines Agency schedules Lamtidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08394MIG.

UNSPSC 51171947 Lamtidine (Commodity) covers pharmaceutical procurement activity in which state and local governments and cooperative purchasing organizations acquire lamtidine—an antiretroviral agent used in HIV treatment regimens—typically as part of broader generic pharmaceutical or specialty drug sourcing efforts. State and local issuing bodies soliciting under this code include county corrections departments managing offender health services, state health and human services agencies administering pharmacy benefit programs, and multistate cooperative purchasing alliances coordinating pharmaceutical procurement across member jurisdictions. The scope of work encompasses product supply with National Drug Code specifications, compliance with current Good Manufacturing Practices and Drug Supply Chain Security Act requirements, and fulfillment through authorized pharmaceutical wholesalers. Pricing models vary, ranging from per-test ancillary charges within clinical laboratories to wholesale net pricing and WAC-minus structures for direct-to-manufacturer or cooperative purchasing arrangements. Performance requirements include maintaining FDA certification, demonstrating chargeback capabilities with multiple authorized distributors, and adhering to contract pricing without surcharges unless triggered by medical inflation indices or competitive repricing triggers.

Recent activity shows procurement concentrated in Texas and the multistate Upper Midwest. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, with a due date of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed to participating state and local government facilities including Oregon, with awarded vendors effective July 1, 2026. Collin County Community Supervision and Corrections Department in Texas released RFP 2026-327 on July 9, 2026, due July 23, 2026, seeking offender specimen collection and drug testing services with an estimated contract value of $600,000 over two years plus optional renewals; while the solicitation centers on specimen collection and testing rather than lamtidine supply per se, the scope includes ancillary pharmaceutical testing methodologies. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capability information on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling future formal procurement for direct pharmaceutical sourcing outside traditional PBM and GPO channels.